- Home
- IVA vs MYGN Comparison
IVA vs MYGN Comparison
Compare IVA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- MYGN
- Stock Information
- Founded
- IVA 2011
- MYGN 1991
- Country
- IVA France
- MYGN United States
- Employees
- IVA N/A
- MYGN N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IVA Health Care
- MYGN Health Care
- Exchange
- IVA Nasdaq
- MYGN Nasdaq
- Market Cap
- IVA 769.0M
- MYGN 642.0M
- IPO Year
- IVA 2020
- MYGN 1995
- Fundamental
- Price
- IVA $6.24
- MYGN $7.99
- Analyst Decision
- IVA Strong Buy
- MYGN Hold
- Analyst Count
- IVA 7
- MYGN 13
- Target Price
- IVA $16.00
- MYGN $13.50
- AVG Volume (30 Days)
- IVA 61.2K
- MYGN 1.5M
- Earning Date
- IVA 09-29-2025
- MYGN 11-06-2025
- Dividend Yield
- IVA N/A
- MYGN N/A
- EPS Growth
- IVA N/A
- MYGN N/A
- EPS
- IVA N/A
- MYGN N/A
- Revenue
- IVA $19,929,536.00
- MYGN $832,900,000.00
- Revenue This Year
- IVA N/A
- MYGN $0.17
- Revenue Next Year
- IVA N/A
- MYGN $6.19
- P/E Ratio
- IVA N/A
- MYGN N/A
- Revenue Growth
- IVA N/A
- MYGN 3.83
- 52 Week Low
- IVA $1.60
- MYGN $3.76
- 52 Week High
- IVA $6.55
- MYGN $26.60
- Technical
- Relative Strength Index (RSI)
- IVA 60.61
- MYGN 63.91
- Support Level
- IVA $5.59
- MYGN $7.04
- Resistance Level
- IVA $6.55
- MYGN $7.97
- Average True Range (ATR)
- IVA 0.33
- MYGN 0.38
- MACD
- IVA 0.01
- MYGN -0.03
- Stochastic Oscillator
- IVA 78.02
- MYGN 78.84
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.